THE LEEDS TEACHING HOSPITALS NATIONAL HEALTH SERVICE TRUST

Their core work

Leeds Teaching Hospitals is one of the largest NHS trusts in the UK, operating major hospitals in Leeds that serve over a million patients annually. In H2020, they contribute clinical expertise, patient cohorts, and real-world healthcare data to European research consortia — particularly in diabetes management, drug safety imaging, autoimmune disorders, and digital pathology. Their value lies in bridging the gap between laboratory research and frontline patient care, providing clinical trial sites and validated patient data that academic-only institutions cannot offer. More recently, they have become a contributor to large-scale AI and digital pathology infrastructure projects.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2018) centred on diabetes — both the metabolic disease itself (diabetic kidney disease biomarkers in BEAt-DKD) and diabetes technology (artificial pancreas for children in KidsAP) — alongside drug safety imaging. From 2018 onward, participation broadened significantly into immune disorders, rare diseases, spinal implant materials (NU-SPINE), and most notably digital pathology with AI (BIGPICTURE in 2021). The shift suggests a hospital increasingly investing in data-driven and AI-enabled clinical research rather than purely disease-specific trials.

Leeds Teaching Hospitals is moving toward large-scale digital health infrastructure and AI-assisted diagnostics, making them a strong partner for projects requiring clinical AI validation at scale.

How they like to work

They never coordinate projects — all 8 involvements are as participant, partner, or third party, which is typical for NHS trusts that contribute clinical resources rather than lead research design. Half their projects (4 of 8) are as third-party contributors, suggesting they often provide specific clinical data, patient cohorts, or specialist expertise to existing consortia rather than being core consortium architects. With 168 unique partners across 21 countries, they are well-networked but function as a sought-after clinical validation site rather than a consortium driver.

They have collaborated with 168 distinct partners across 21 countries, indicating deep integration into European health research networks. Their partnerships span academic hospitals, pharmaceutical companies (through IMI-linked projects like BEAt-DKD and TRISTAN), and university research groups.

What sets them apart

As a major NHS teaching hospital trust, Leeds offers something most research partners cannot: direct access to large, diverse patient populations within a publicly funded healthcare system, combined with clinical infrastructure for running trials and collecting real-world evidence. Their dual strength in both established clinical domains (diabetes, haematology) and emerging digital health (AI pathology) makes them particularly valuable for projects that need to validate research tools against actual clinical workflows. For consortium builders, they represent a credible clinical endpoint — the place where research gets tested on real patients.

Highlights from their portfolio

• BIGPICTURE
  Their largest funded project (EUR 950K) and most recent, building a pan-European AI-powered digital pathology repository — signals their strategic direction.
• KidsAP
  Clinically impactful work on artificial pancreas technology for children aged 1-7 with type 1 diabetes, a vulnerable population where clinical trial participation is difficult to secure.
• ImmunAID
  Ambitious multi-omics approach to autoinflammatory disorders integrating inflammasome biology, microbiome analysis, and machine learning — shows breadth beyond their diabetes core.